Network Pharmacology and In Vivo Evaluation of Modified Huanglian Wendan Decoction in Polycystic Ovary Syndrome With Insulin Resistance: Association With AGE–RAGE‐Related Signaling
Chemistry & Biodiversity · 2026
DOI: 10.1002/cbdv.71737 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2026. Verfasst von Xi Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Insulin Resistance, Drugs, Chinese Herbal, Receptor for Advanced Glycation End Products. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Center for Traditional Chinese Medicine Science and Technology Development, Scientific Research Funding Project of Wuhan Municipal Health Commission, the Wuhan Municipal Science and Technology Innovation Bureau.
Abstract (Originalsprache)
Modified Huanglian Wendan Decoction (HLWDD) is used for polycystic ovary syndrome with insulin resistance (PCOS‐IR), but its biological basis remains incompletely defined. This study integrated network pharmacology, molecular docking, 100‐ns molecular dynamics (MD), batch‐specific chemical characterization, and in vivo evaluation in a letrozole/high‐fat diet rat model. HPLC fingerprinting showed high batch reproducibility, while UHPLC–HRMS/MS identified 997 candidate library assignments, including 118 higher‐confidence features. Network analysis identified 136 candidate compounds and 532 overlapping PCOS‐related targets, prioritizing AGE–RAGE signaling. Representative docked complexes remained stable during MD and showed negative MM/PBSA binding free energies. In vivo, HLWDD improved estrous‐cycle recovery and ovarian morphology, reduced fasting insulin, HOMA‐IR, reproductive hormones, and inflammatory markers, and modulated ovarian AGE, RAGE, STAT3, and AKT1 expression. High‐dose HLWDD also reduced p‐STAT3/STAT3 and increased p‐AKT/AKT1 relative to the Model group. These findings support an association between HLWDD treatment and AGE–RAGE/STAT3/AKT‐related signaling without establishing causal pathway mediation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Traditional Chinese Medicine, Hubei University of Chinese Medicine, Wuhan, China.
- Department of Gynecology, Wuhan Hospital of Traditional Chinese Medicine, Wuhan, China.
- Wuhan Hospital of Traditional Chinese Medicine, Wuhan, China.
ORCID-Profile: Chenghong Zheng
Förderung
- China Center for Traditional Chinese Medicine Science and Technology Development
- Scientific Research Funding Project of Wuhan Municipal Health Commission
- the Wuhan Municipal Science and Technology Innovation Bureau
- the Hubei Provincial Department of Science and Technology
Zitieren
APA
Chen, X., Yang, X., Wang, X., Chou, D., & Zheng, C. (2026). Network Pharmacology and In Vivo Evaluation of Modified Huanglian Wendan Decoction in Polycystic Ovary Syndrome With Insulin Resistance: Association With AGE–RAGE‐Related Signaling. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.71737
Vancouver
Chen X, Yang X, Wang X, Chou D, Zheng C. Network Pharmacology and In Vivo Evaluation of Modified Huanglian Wendan Decoction in Polycystic Ovary Syndrome With Insulin Resistance: Association With AGE–RAGE‐Related Signaling. Chemistry & Biodiversity. 2026. doi:10.1002/cbdv.71737
BibTeX
@article{Chen2026,
author = {Chen, Xi and Yang, Xing and Wang, Xinni and Chou, Dan and Zheng, Chenghong},
title = {Network Pharmacology and In Vivo Evaluation of Modified Huanglian Wendan Decoction in Polycystic Ovary Syndrome With Insulin Resistance: Association With AGE–RAGE‐Related Signaling},
journal = {Chemistry & Biodiversity},
year = {2026},
doi = {10.1002/cbdv.71737}
}
EUVIMED